Base de dados : MEDLINE
Pesquisa : D06.472.699.327.740.320.790 [Categoria DeCS]
Referências encontradas : 1807 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 181 ir para página                         

  1 / 1807 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771155
[Au] Autor:Sükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoglu CS
[Ad] Endereço:Department of Obstetrics and Gynecology, Ankara University School of Medicine, Kadin Hastaliklari ve Dogum AD, 06100 Cebeci, Ankara, Turkey.
[Ti] Título:Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
[So] Source:Reprod Biomed Online;34(1):5-10, 2017 Jan.
[Is] ISSN:1472-6491
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/agonistas
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Oócitos/citologia
Síndrome de Hiperestimulação Ovariana/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estradiol/sangue
Feminino
Antagonistas de Hormônios/uso terapêutico
Seres Humanos
Infertilidade Feminina/terapia
Infertilidade Masculina/terapia
Leuprolida/administração & dosagem
Masculino
Oócitos/efeitos dos fármacos
Oogênese
Indução da Ovulação
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Risco
Injeções de Esperma Intracitoplásmicas
Pamoato de Triptorrelina/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hormone Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone); 4TI98Z838E (Estradiol); 57773-63-4 (Triptorelin Pamoate); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  2 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28541153
[Au] Autor:Summa NM; Guzman DS; Wils-Plotz EL; Riedl NE; Kass PH; Hawkins MG
[Ti] Título:Evaluation of the effects of a 4.7-mg deslorelin acetate implant on egg laying in cockatiels (Nymphicus hollandicus).
[So] Source:Am J Vet Res;78(6):745-751, 2017 Jun.
[Is] ISSN:1943-5681
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE To evaluate effects of administration of a 4.7-mg deslorelin acetate implant on egg laying in healthy cockatiels (Nymphicus hollandicus). ANIMALS 52 cockatiels. PROCEDURES 26 breeding pairs (a female and its respective male in each pair) were selected on the basis of their history of egg laying. Female birds were sedated and received a 4.7-mg deslorelin acetate implant (n = 13) or placebo implant (13) in the subcutaneous tissues between the scapulae. Male and female birds of each breeding pair were placed in separate but adjacent cages. Birds were exposed to 16 hours of light and 8 hours of darkness. A nest box was placed in cages of female birds to stimulate reproductive activity. Egg production and quality were monitored daily for 365 days. RESULTS Deslorelin acetate implants significantly suppressed egg laying in cockatiels, compared with effects for the placebo implants. Eleven of 13 placeboimplanted birds laid eggs between 12 and 42 days after implantation. None of the deslorelin-implanted birds laid eggs within 180 days after implantation, and only 5 of 13 deslorelin-implanted birds laid an egg during the study period (first egg laid between 192 and 230 days after implantation). No differences in egg quality or number of eggs per clutch were observed between the 2 groups. CONCLUSIONS AND CLINICAL RELEVANCE Insertion of a 4.7-mg deslorelin acetate implant suppressed egg laying in healthy cockatiels for at least 180 days. Studies are necessary to evaluate effects of a deslorelin acetate implant in other avian species or in association with reproductive disorders.
[Mh] Termos MeSH primário: Cacatuas
Oviposição/efeitos dos fármacos
Pamoato de Triptorrelina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Cruzamento
Implantes de Medicamento
Feminino
Masculino
Óvulo
Reprodução
Pamoato de Triptorrelina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Implants); 57773-63-4 (Triptorelin Pamoate); TKG3I66TVE (deslorelin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.2460/ajvr.78.6.745


  3 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28261833
[Au] Autor:Sukumar SP; Bhansali A; Sachdeva N; Ahuja CK; Gorsi U; Jarial KD; Walia R
[Ad] Endereço:Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
[Ti] Título:Diagnostic utility of testosterone priming prior to dynamic tests to differentiate constitutional delay in puberty from isolated hypogonadotropic hypogonadism.
[So] Source:Clin Endocrinol (Oxf);86(5):717-724, 2017 May.
[Is] ISSN:1365-2265
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Differentiation between constitutional delay in puberty (CDP) and isolated hypogonadotropic hypogonadism (IHH) during adolescence is a great clinical challenge, and the available diagnostic tests are of limited value. OBJECTIVE: To study the effect of withdrawal of short-term, low-dose testosterone therapy (testosterone priming) on the discriminatory power of dynamic tests for hypothalamo-pituitary-testicular axis to differentiate CDP from IHH. DESIGN: A prospective study (n = 30) consisting of 20 boys with delayed puberty (group A) and 10 patients with IHH (group B). INTERVENTION: Patients in groups A and B underwent Triptorelin and hCG stimulation tests, prior to and 2 months after withdrawal of 'testosterone priming' (100 mg intramuscularly 4 weekly for 3 months) and were followed up until the onset of puberty or 18 years of age, whichever was earlier. RESULTS: At baseline, Triptorelin-stimulated 4 h LH, with a cut-off of 2·8 IU/l, and hCG-stimulated day 7 testosterone with a cut-off of 3·8 nmol/l had sensitivities of 80% each, and specificities of 93% and 87%, respectively, to diagnose CDP. After withdrawal of testosterone, a 4 h LH cut-off of 14·7 IU/l and day 7 testosterone cut-off of 10·3 nmol/l had sensitivities of 93% and 88% respectively, and specificity and positive predictive value of 100% each. A basal inhibin B > 94·7 ng/l was discriminatory for diagnosing CDP after withdrawal of testosterone priming. CONCLUSIONS: Inhibin B levels or 4 h LH after Triptorelin stimulation are the best discriminatory tests to differentiate CDP from IHH, when performed after withdrawal of 'testosterone priming'.
[Mh] Termos MeSH primário: Hipogonadismo/sangue
Hipogonadismo/diagnóstico
Valor Preditivo dos Testes
Puberdade Tardia/sangue
Puberdade Tardia/diagnóstico
Testosterona/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Diagnóstico Diferencial
Seguimentos
Seres Humanos
Inibinas
Hormônio Luteinizante/sangue
Luteolíticos/administração & dosagem
Masculino
Pamoato de Triptorrelina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Luteolytic Agents); 0 (inhibin B); 3XMK78S47O (Testosterone); 57285-09-3 (Inhibins); 57773-63-4 (Triptorelin Pamoate); 9002-67-9 (Luteinizing Hormone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE
[do] DOI:10.1111/cen.13321


  4 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28237336
[Au] Autor:Knox RV; Esparza-Harris KC; Johnston ME; Webel SK
[Ad] Endereço:Department of Animal Science, University of Illinois, Urbana, IL, USA. Electronic address: rknox@illinois.edu.
[Ti] Título:Effect of numbers of sperm and timing of a single, post-cervical insemination on the fertility of weaned sows treated with OvuGel .
[So] Source:Theriogenology;92:197-203, 2017 Apr 01.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Variability in estrus and ovulation requires multiple inseminations during estrus to ensure one AI occurs close to ovulation. Induction of ovulation after weaning improves synchrony of ovulation and allows for fixed time AI. However, the interaction between number of sperm in the AI dose and the timing of insemination has not been fully investigated. The objective of this study was to determine the effects of sperm numbers used in a single post-cervical insemination (PCAI) and the timing of insemination following induced ovulation in weaned sows. The experiment was performed using sows (n = 641) allotted by parity (1-6) and lactation length (19.5 d) to receive a single PCAI using 1.5 or 2.5 billion motile sperm at either 22, 26, or 30 h following administration of a GnRH agonist, triptorelin acetate (OvuGel ) at 96 h post-weaning. Sows received boar contact once daily 3-6 d following weaning. A sub-population of the sows (n = 499) were assessed for follicle size and ovulation utilizing ultrasound at 8 h intervals. There was no interaction of number of sperm and timing of insemination for any response measure (P > 0.10). Wean to estrus interval (4.8 d), duration of estrus (1.9 d), and expression of estrus (88.0%), were not different among treatments (P > 0.10). Of sows scanned by ultrasound at the time of OvuGel , 88.2% had large follicles, 10.9% had small, medium or cystic sized follicles, and 0.9% had corpora lutea. The proportion of sows that ovulated averaged 94%, and differed by time of AI (P ≤ 0.05) but not by number of sperm. Pregnancy rate and farrowing rate tended to be affected by dose (P ≤ 0.10), while time of insemination affected pregnancy rate and tended to influence farrowing rate (P ≤ 0.10). Farrowing rate was greater (P < 0.0001) with use of 2.5 than 1.5 billion sperm and insemination at 22 and 26 h compared to 30 h after OvuGel (P ≤ 0.10). Farrowing rate was also affected by parity, estrus expression, ovulation and ovarian abnormalities (P < 0.05). Of the 12% of weaned sows that did not exhibit estrus, approximately 50% farrowed a litter. Total born and born alive were affected by dose (P < 0.05) but not time of insemination with both measures increased with 2.5 compared to 1.5 billion sperm (P < 0.05). The results of this study indicate that induction of ovulation in weaned sows resulted in 88% of sows ovulating within a 24 h period. Fertility was improved with a single, fixed time AI using 2.5 compared to 1.5 billion motile sperm and insemination at 22-26 h after OvuGel compared to 30 h.
[Mh] Termos MeSH primário: Fertilidade/efeitos dos fármacos
Inseminação Artificial/veterinária
Luteolíticos/farmacologia
Suínos/fisiologia
Pamoato de Triptorrelina/farmacologia
[Mh] Termos MeSH secundário: Animais
Feminino
Tamanho da Ninhada de Vivíparos
Luteolíticos/administração & dosagem
Masculino
Parto
Pamoato de Triptorrelina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Luteolytic Agents); 57773-63-4 (Triptorelin Pamoate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170227
[St] Status:MEDLINE


  5 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28028737
[Au] Autor:Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
[Ad] Endereço:Loretto Hospital, Freiburg, Germany.
[Ti] Título:Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
[So] Source:Adv Ther;34(2):513-523, 2017 Feb.
[Is] ISSN:1865-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to <50 ng/dl has been established over decades. Evidence is growing though that suppression to even lower levels may add further clinical benefit. Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards. METHODS: Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled. Patients aged 42-96 years had to be eligible for ADT and to be either naïve to hormonal treatment or have undergone appropriate washout prior to enrolment. Patients were treated with triptorelin SR formulations for 2-12 months. Primary endpoints of this analysis were serum testosterone concentrations under treatment and success rates overall and per formulation, based on a testosterone target threshold of 20 ng/dl. RESULTS: After 1, 3, 6, 9, and 12 months of treatment, 79%, 92%, 93%, 90%, and 91% of patients reached testosterone levels <20 ng/dl, respectively. For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively. CONCLUSION: In the large majority of patients, triptorelin SR formulations suppressed serum testosterone concentrations to even <20 ng/dl. Testosterone should be routinely monitored in PC patients on ADT although further studies on the clinical benefit of very low testosterone levels and the target concentrations are still warranted.
[Mh] Termos MeSH primário: Neoplasias da Próstata
Testosterona/sangue
Pamoato de Triptorrelina
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos Hormonais/administração & dosagem
Antineoplásicos Hormonais/farmacologia
Disponibilidade Biológica
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/farmacologia
Hormônio Liberador de Gonadotropina/agonistas
Seres Humanos
Masculino
Meia-Idade
Estadiamento de Neoplasias
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/patologia
Estudos Retrospectivos
Resultado do Tratamento
Pamoato de Triptorrelina/administração & dosagem
Pamoato de Triptorrelina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Delayed-Action Preparations); 33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone); 57773-63-4 (Triptorelin Pamoate); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:161229
[St] Status:MEDLINE
[do] DOI:10.1007/s12325-016-0466-7


  6 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28025851
[Au] Autor:Goericke-Pesch S
[Ad] Endereço:Section for Veterinary Reproduction and Obstetrics, Department Large Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.
[Ti] Título:Long-term effects of GnRH agonists on fertility and behaviour.
[So] Source:Reprod Domest Anim;52 Suppl 2:336-347, 2017 Apr.
[Is] ISSN:1439-0531
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:This review aimed to summarize the present knowledge about the effects of GnRH agonist slow-release implants (GnRH A-SRI) on fertility and behaviour in male and female dogs and cats with special focus on deslorelin. Following an initial stimulation of gonadotropin and testosterone secretion possibly associated with an improved semen quality, GnRH A-SRI induce long-term depression of fertility in male dogs and cats with, however, a large individual variation in onset and duration of efficacy especially in cats. The GnRH A-SRI furthermore interfere with testosterone-dependent/affected behaviour; a significant positive effect in reducing sexual behaviour and libido, hypersexuality, intermale dominance and excessive territorial urine marking has been described. Rates of improvement of the respective behaviour are comparable to those after surgical castration, making GnRH A-SRI a valuable option to predict castration-related effects on behaviour and to identify animals where surgical castration will not be beneficial. No effect has been seen in reducing aggression towards humans indicating the need for behavioural therapy to control this problem. Effects on spermatogenesis, steroidogenesis and behaviour have by now been shown to be fully reversible. Knowledge in females is more limited, and particularly, the initial induction of a possibly fertile oestrus and individual variation in duration of efficacy remain problems in bitches and queens treated for suppression of fertility. However, long-term suppression of oestrous cycle and fertility seems to be possible with induced effects shown to be reversible including restoration of normal fertility after the end of efficacy/GNRH A-SRI removal.
[Mh] Termos MeSH primário: Comportamento Animal/efeitos dos fármacos
Gatos
Cães
Fertilidade/efeitos dos fármacos
Hormônio Liberador de Gonadotropina/agonistas
[Mh] Termos MeSH secundário: Animais
Anticoncepção/métodos
Anticoncepção/veterinária
Preparações de Ação Retardada
Implantes de Medicamento
Ciclo Estral/efeitos dos fármacos
Feminino
Masculino
Espermatogênese/efeitos dos fármacos
Pamoato de Triptorrelina/administração & dosagem
Pamoato de Triptorrelina/análogos & derivados
Pamoato de Triptorrelina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Drug Implants); 33515-09-2 (Gonadotropin-Releasing Hormone); 57773-63-4 (Triptorelin Pamoate); TKG3I66TVE (deslorelin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161228
[St] Status:MEDLINE
[do] DOI:10.1111/rda.12898


  7 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Lopes, Maria Denise
Texto completo
[PMID]:27913778
[Au] Autor:Ackermann CL; Trevisol E; Crocomo LF; Rascado TDS; Volpato R; Guaitolini CRF; Lopes C; Costa TA; Lopes MD
[Ad] Endereço:1 Department of Animal Reproduction and Veterinary Radiology, Faculty of Veterinary Medicine and Animal Science, Faculty of Veterinary Medicine and Animal Science/São Paulo State University, Botucatu, Brazil.
[Ti] Título:Effect of deslorelin acetate treatment in oocyte recovery and in vitro embryo production in domestic cats.
[So] Source:J Feline Med Surg;19(10):1091-1095, 2017 Oct.
[Is] ISSN:1532-2750
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives The present study investigated the effect of contraceptive treatment with deslorelin acetate on in vitro embryo production and oocyte recovery in domestic queens. Methods Twenty-one mature domestic cats were used. Eleven queens (treated group) and one tom were kept in an experimental cattery, and 10 queens were privately owned (control group). When in interestrus or diestrus (day 0) a deslorelin acetate implant (Suprelorin, 4.7 mg/animal) was inserted into the subcutaneous tissue of the interscapular region in all queens in the treated group. After 6 months of treatment, all animals were ovariohysterectomized, and the ovaries were used for in vitro embryo production. Percentage of cleavage was determined 18 h after oocyte insemination and blastocyst formation was assessed on the eighth day of culture. The rate of cumulus-oocyte complexes (COCs) recovery was analyzed by an unpaired t-test. The cleavage and blastocyst rates were expressed as percentages and analyzed by Fisher's exact test. All analyses were performed using GraphPad Prism v5.0, with P <0.05 set as the level of significance. Results In the treated group, we recovered 8.3 ± 1.15 grade I COCs per queen; the cleavage rate was 60% and the blastocyst rate was 36%. In the control group, we recovered 18.4 ± 3.21 grade I COCs per queen; the cleavage rate was 55.97% and the blastocyst rate was 34%. Forty percent of treated females did not produce any blastocysts. In the treated group, we observed a significant decrease in COC recovery. Although there was no significant difference in cleavage and blastocyst rates between groups, 40% of treated females did not produce any blastocysts. Conclusions Recovery of grade I COCs is negatively affected by deslorelin treatment in domestic cats. Regarding embryo production, new studies are still necessary to evaluate the success of this technique owing to the individual effect caused by deslorelin acetate.
[Mh] Termos MeSH primário: Fertilização In Vitro/veterinária
Recuperação de Oócitos/veterinária
Oócitos/efeitos dos fármacos
Pamoato de Triptorrelina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Blastocisto/citologia
Blastocisto/fisiologia
Gatos
Feminino
Fertilização In Vitro/métodos
Recuperação de Oócitos/métodos
Oócitos/citologia
Pamoato de Triptorrelina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
57773-63-4 (Triptorelin Pamoate); TKG3I66TVE (deslorelin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161204
[St] Status:MEDLINE
[do] DOI:10.1177/1098612X16680697


  8 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27892642
[Au] Autor:Rhodes L
[Ad] Endereço:Alliance for Contraception in Cats and Dogs Board of Directors, Member Scientific Advisory Board, Found Animals Foundation, Durham, NH, USA.
[Ti] Título:New approaches to non-surgical sterilization for dogs and cats: Opportunities and challenges.
[So] Source:Reprod Domest Anim;52 Suppl 2:327-331, 2017 Apr.
[Is] ISSN:1439-0531
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Over the last 40 years, researchers have explored methods to non-surgically suppress fertility in animals. Immunocontraception has been used to control wildlife populations but does not confer long-term immunity. The gonadotropin-releasing hormone (GnRH) agonist deslorelin, formulated as an implant to provide 6-month to 1-year suppression of fertility in male dogs, is available commercially in some countries. Neither of these approaches provide permanent sterility. A single-dose, permanent treatment would be a valuable tool in dog and cat population control. The Michelson Prize and Grants (MPG) programme was initiated "to eliminate shelter euthanasia of healthy, adoptable companion animals and reduce populations of feral and free-roaming cats and dogs" offering a $25 million US prize for a non-surgical sterilant that is effective as a single treatment in both male and female dogs and cats. Michelson Prize and Grants programme has offered US $50 million in grant money for research and has attracted scientists worldwide. Approaches under study include gene therapy, small interfering RNA to inhibit reproductive targets and delivery of cytotoxins to pituitary gonadotrophs or GnRH producing neurons in the hypothalamus. Research in implant technology that could deliver compounds over an animal's lifetime is also underway. Details of funded grants and results to date can be found at: http://www.michelsonprizeandgrants.org/michelson-grants/research-findings. The next steps are translating the most promising research into products. The Alliance for Contraception of Cats and Dogs (ACC&D) is helping to research practical methods of marking sterilized animals to avoid costly retreatment and population modelling that will help guide field workers in use of resources for sterilization programmes.
[Mh] Termos MeSH primário: Gatos
Cães
Esterilização Reprodutiva/veterinária
[Mh] Termos MeSH secundário: Animais
Distinções e Prêmios
Anticoncepção/veterinária
Anticoncepção Imunológica/veterinária
Anticoncepcionais/administração & dosagem
Citotoxinas/administração & dosagem
Implantes de Medicamento
Feminino
Inativação Gênica
Hormônio Liberador de Gonadotropina/agonistas
Infertilidade
Masculino
Controle da População/métodos
RNA Interferente Pequeno/administração & dosagem
Apoio à Pesquisa como Assunto
Esterilização Reprodutiva/métodos
Pamoato de Triptorrelina/administração & dosagem
Pamoato de Triptorrelina/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents); 0 (Cytotoxins); 0 (Drug Implants); 0 (RNA, Small Interfering); 33515-09-2 (Gonadotropin-Releasing Hormone); 57773-63-4 (Triptorelin Pamoate); TKG3I66TVE (deslorelin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161129
[St] Status:MEDLINE
[do] DOI:10.1111/rda.12862


  9 / 1807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27743690
[Au] Autor:Mehl NS; Srisuwatanasagul S; Swangchan-Uthai T; Sirivaidyapong S; Khalid M
[Ad] Endereço:Department of Obstetrics, Gynaecology, and Reproduction, Chulalongkorn University, Bangkok, Thailand.
[Ti] Título:GnRH-agonist implants suppress reproductive function and affects ovarian LHR and FSHR expression in prepubertal female cats.
[So] Source:Theriogenology;87:250-258, 2017 Jan 01.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Effect of a GnRH-agonist (deslorelin) was studied on reproductive function and ovarian luteinizing hormone receptor (LHR) and follicle stimulating hormone receptor (FSHR) expression in prepubertal female cats that were either implanted with 4.7-mg deslorelin (implanted: n = 6) or not (controls: n = 18) or ovariohysterectomized at prepubertal age (prepubertal OVH: n = 6). Body weights, fecal estradiol, and sexual behavior of implanted and control cats were monitored for 48 weeks followed by collection of ovaries and uteri. Ovaries and uteri were collected from control cats at follicular, luteal, and inactive stage (n = 6/group) and from prepubertal OVH cats at prepubertal age. Ovaries and uteri were analyzed for anatomical/histological characteristics. Ovaries were also analyzed for LHR and FSHR expression. Statistical analysis showed higher (P ≤ 0.05) body weight in control than implanted cats only during 22nd to 26th weeks of the study. Estrus was observed in control cats only. Deslorelin reduced (P ≤ 0.05) ovarian weight and number of antral follicles but did not affect endometrial thickness and gland diameter. However, myometrial thickness of implanted cats was significantly lower than control cats at follicular and luteal stage. Ovarian LHR mRNA expression was lower (P ≤ 0.05) in implanted cats than control cats at follicular stage. FSHR mRNA and LHR protein expression did not differ among the three groups. FSHR protein expression was lower (P ≤ 0.05) in prepubertal OVH cats and was not affected by deslorelin. In conclusion, deslorelin suppresses reproductive function in prepubertal female cats for at least 48 weeks possibly through a change in the ovarian mRNA expression of LHR.
[Mh] Termos MeSH primário: Gatos/fisiologia
Ovário/efeitos dos fármacos
Receptores do FSH/metabolismo
Receptores do LH/metabolismo
Pamoato de Triptorrelina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Implantes de Medicamento
Feminino
Expressão Gênica
Maturidade Sexual
Pamoato de Triptorrelina/administração & dosagem
Pamoato de Triptorrelina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Implants); 0 (Receptors, FSH); 0 (Receptors, LH); 57773-63-4 (Triptorelin Pamoate); TKG3I66TVE (deslorelin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161017
[St] Status:MEDLINE


  10 / 1807 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26919403
[Au] Autor:de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J; Triptocare LT Study Group
[Ad] Endereço:INSERM U955 Eq07, Department of Urology, CHU Henri Mondor Assistance Publique des Hopitaux de Paris, Créteil, France.
[Ti] Título:Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
[So] Source:BJU Int;119(1):74-81, 2017 Jan.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess time to progression to castrate-resistant prostate cancer (CRPC) and factors influencing longer-term outcomes in patients receiving androgen-deprivation therapy (ADT) in an extension to the Triptocare study (NCT01020448). This is pertinent as the Triptocare study did not show that urinary prostate cancer antigen-3 (PCA3) score was a reliable marker of cancer stage in advanced prostate cancer and was not useful for assessing response 6 months after initiation of ADT with triptorelin 22.5 mg. PATIENTS AND METHODS: An international, multicentre, non-interventional, observational, longitudinal, prospective study involving patients from the Triptocare study. CRPC status of patients was collected for up to 3 years from ADT initiation. Patient treatment and assessments were at the investigator's discretion. Co-primary endpoints were rate of CRPC at 3 years after initiating ADT and the median time to CRPC. An exploratory endpoint was the association of Triptocare baseline variables (including TMPRSS2-ERG and PCA3 scores) and PCA3 score at Triptocare last value available with CRPC onset. RESULTS: Of the 325 patients in the Triptocare study safety population, 180 patients were enrolled in the Triptocare LT study (102 received continuous and 78 received intermittent ADT). CRPC rates at 3 years were 24/102 (23.5%) and 6/78 (7.7%) patients in the continuous and intermittent ADT groups, respectively. The median time to CRPC was not reached for either group. PCA3 score status at baseline was the only variable associated with a higher risk of progression to CRPC in both the intermittent and continuous ADT groups; compared with a baseline PCA3 score of ≥35, a PCA3 score below the level of quantification had a hazard ratio (HR) of 20.04 ([95% confidence interval (CI) 2.71-148.34] and a HR of 9.44 [95% CI 2.39-37.27], respectively). Baseline metastatic disease and testosterone level were additionally associated with progression to CRPC in the continuous ADT population (HR 5.20, 95% CI 1.68-16.06 and HR 0.995, 95% CI 0.991-0.999, respectively). CONCLUSION: In men with locally advanced or metastatic prostate cancer, a PCA3 score of ≥35 at the time of initiating ADT may predict a lower risk of developing CRPC in the following 3 years.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/uso terapêutico
Hormônio Liberador de Gonadotropina/análogos & derivados
Neoplasias de Próstata Resistentes à Castração/etiologia
Neoplasias da Próstata/complicações
Pamoato de Triptorrelina/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Progressão da Doença
Seres Humanos
Estudos Longitudinais
Masculino
Meia-Idade
Prognóstico
Estudos Prospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 33515-09-2 (Gonadotropin-Releasing Hormone); 57773-63-4 (Triptorelin Pamoate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170524
[Lr] Data última revisão:
170524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160227
[St] Status:MEDLINE
[do] DOI:10.1111/bju.13455



página 1 de 181 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde